原始出處紀錄
決策級其他
Lilly 將收購 AtaiBeckley 以取得 BPL-003 用於 TRD
Lilly 簽署最終協議收購 AtaiBeckley，取得 BPL-003（mebufotenin benzoate 鼻噴劑）及 VLS-01（DMT 口腔膜）用於治療抗藥性憂鬱症。交易包括 28 億美元前期股權價值，以及最高 10 億美元的 CVR 里程碑付款，與第三期試驗啟動及美國核准掛鉤。BPL-003 已獲得突破性療法認定，並已啟動第三期試驗相關活動。
關鍵事實
來源摘錄
EX-99.1 4 ef20078103_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 July 16, 2026 For Release: Immediately Refer to: Jessica Bardoulas; jessica.bardoulas@lilly.com ; (Media) Michael Czapar; czapar_michael_c@lilly.com ; (Investors) Jason Awe, PhD; Jason.Awe@ataibeckley.com (Investors) Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 – Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company develop